


OncoIndx[®] Prime⁺ is a Comprehensive Tissue-Liquid-Normal match genomic test which performs molecular profiling of tumor and normal samples simultaneously from the same patient.



Why Tissue-Liquid-Normal match?

- Identification of true somatic and true germline mutations
- Identification of fusions by DNA and RNA
- RNA-based gene expression on tissue
- High accuracy of TMB, MSI, and HRD with the patient's normal matched sample
- Accurate identification of reversal and Clonal hematopoiesis of indeterminate potential (CHIP) mutations
- High accuracy in detecting copy number variation (CNV)
- Single comprehensive test to address complex molecular questions in cancer patients

OncoIndx[®] Prime⁺ in practice

- Challenges of managing treatment responses are addressed through tissue-liquid-normal match derived treatment choices.
- Tissue-liquid-normal match NGS report enhanced with AI and updated clinical studies help identify the most beneficial therapeutic options.

Clinical and Technical Validation of OncoIndx[®] Assay

Alteration	* PPV	* NPV	Accuracy	Specificity	Sensitivity
SNVs	100	100	100	100	100
Small INDELs	100	94.03	97.40	100	95.60
CNA	100	100	100	100	100
Fusions	100	96.43	98.48	100	97.44

Transcriptomics Validation Results


Sensitivity	* PPV	* NPV	Specificity	Concordance
86.7%	100%	100%	93.6%	95%

A total of 165 samples including reference standards, clinical, cross-laboratory and TCGA samples.

* NPV: Negative predictive value. PPV: Positive predictive value.

Designed for oncologists managing complex, advanced and refractory cancer patients.

- Proprietary panel of 1,000+ genes
- Tissue-liquid-normal matched
- RNA-based fusion, RNA expressed Variants, Splice Variants and gene expression (TBx)
- Longitudinal monitoring markers
- PD-L1 through IHC (TBx) / immunofluorescence on CTCs (LBx)
- CTC enumeration



When to use the OncoIdx® Prime+ ?

- 01 Advanced Stage Cancers

Including progressive and treatment-resistant tumors
- 02 Rare Cancers

Sarcoma, Glioma to identify clinical-trial enrolment or off-label therapy
- 03 Cancers of Unknown Primary (CUP)

RNA-based gene expression analysis supports tissue-of-origin identification
- 04 Multiple or Dual Malignancies


Distinguish between independent primary tumors and metastatic outcome
- 05 Biomarker Profiling

Patient selection for treatment with Immunotherapy/ Targeted therapy

Features of OncoIdx® Prime+ report

- In accordance to international guidelines.
- Clear, unambiguous and actionable genomic findings.
- Based on highly reliable and internally curated databases.
- Precise reporting of tumor-derived, germline, reversal and CHIP mutations.
- Tumor Fraction

OncoIdx® Prime+ Workflow



OncoIdx® Prime+ is a well-validated Tissue-Liquid-Normal match NGS test to extract therapy information for the patient. It is possible on both tissue as well as blood sample.

1000+ genes panel

This tissue-liquid- normal matched NGS test includes 1000+ genes of targetable/ therapeutic significance.

>99% on target coverage

The test has a mean coverage of 98-100% across all tested genes.

2000x / 10000x mean depth

The test is performed at a mean depth of 2000x for tissue samples and 10000x for blood.

